Amylyx Pharmaceuticals(AMLX)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

AMLX Amylyx Pharmaceuticals

盘前交易 01-12 05:28:43 EST

12.21

+0.38

+3.21%

最高12.50	最低11.77	成交量120.95万
今开11.88	昨收11.83	日振幅6.17%
总市值13.41亿	流通市值7.99亿	总股本1.10亿
成交额1,479万	换手率1.85%	流通股本6,545万
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

{"stockData":{"symbol":"AMLX","market":"US","secType":"STK","nameCN":"Amylyx Pharmaceuticals","latestPrice":12.21,"timestamp":1767992400000,"preClose":11.83,"halted":0,"volume":1209522,"delay":0,"floatShares":65449399,"shares":109819569,"eps":-1.774191,"marketStatus":"盘前交易","change":0.38,"latestTime":"01-12 05:28:43 EST","open":11.88,"high":12.5,"low":11.77,"amount":14790241.844262,"amplitude":0.061708,"askPrice":16.06,"askSize":100,"bidPrice":10.91,"bidSize":100,"shortable":3,"etf":0,"ttmEps":-1.774191,"tradingStatus":1,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1768228200000},"marketStatusCode":1,"adr":0,"adrRate":0,"listingDate":1641531600000,"exchange":"NASDAQ","adjPreClose":12.21,"bidAskSpread":0,"postHourTrading":{"tag":"盘后","latestPrice":12.21,"preClose":12.21,"latestTime":"19:37 EST","volume":110189,"amount":1346895.4423,"timestamp":1768005465885},"volumeRatio":0.6002631680614018,"impliedVol":0.4052,"impliedVolPercentile":0.232},"requestUrl":"/m/hq/s/AMLX","defaultTab":"news","newsList":[{"id":"1105804341","title":"Amylyx Pharmaceuticals提名AMX0318为新型长效GLP-1受体拮抗剂开发候选药物，该成果系与Gubra A/S合作发现","url":"https://stock-news.laohu8.com/highlight/detail?id=1105804341","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1105804341?lang=zh_cn&edition=full","pubTime":"2026-01-08 20:12","pubTimestamp":1767874342,"startTime":"0","endTime":"0","summary":"Amylyx Pharmaceuticals近日正式提名AMX0318作为其新型长效GLP-1受体拮抗剂开发候选药物。这一重要里程碑源于该公司与Gubra A/S的协同研究合作。AMX0318的独特机制有望为代谢性疾病治疗开辟新路径，其长效特性可能显著改善患者用药依从性。此次候选药物提名标志着合作项目正式进入下一阶段开发流程。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AMLX","BK4007"],"gpt_icon":0},{"id":"1177552511","title":"Amylyx Pharmaceuticals发布首例人体试验Lumina试验中Amx0114在ALS中安全性和耐受性Cohort 1的新数据","url":"https://stock-news.laohu8.com/highlight/detail?id=1177552511","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1177552511?lang=zh_cn&edition=full","pubTime":"2025-12-05 22:02","pubTimestamp":1764943357,"startTime":"0","endTime":"0","summary":"Amylyx Pharmaceuticals发布首例人体试验Lumina试验中Amx0114在ALS中安全性和耐受性Cohort 1的新数据","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","AMLX"],"gpt_icon":0},{"id":"2585191191","title":"Amylyx Pharmaceuticals, Inc.盘中异动 股价大跌5.03%报13.60美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2585191191","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2585191191?lang=zh_cn&edition=full","pubTime":"2025-11-21 04:40","pubTimestamp":1763671232,"startTime":"0","endTime":"0","summary":"北京时间2025年11月21日04时40分，Amylyx Pharmaceuticals, Inc.股票出现异动，股价急速下挫5.03%。Amylyx Pharmaceuticals, Inc.股票所在的生物技术行业中，整体涨幅为0.40%。Amylyx Pharmaceuticals, Inc.公司简介：Amylyx Pharmaceuticals Inc 是一家处于临床阶段的制药公司，致力于开发治疗肌萎缩性侧索硬化症和其他神经退行性疾病的新型疗法。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025112104403397762da5&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025112104403397762da5&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4007","AMLX"],"gpt_icon":0},{"id":"1196594315","title":"Amylyx Pharmaceuticals 第三季度每股收益为-0.37美元，超出IBES预期的-0.47美元","url":"https://stock-news.laohu8.com/highlight/detail?id=1196594315","media":"投资观察","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1196594315?lang=zh_cn&edition=full","pubTime":"2025-11-20 00:54","pubTimestamp":1763571253,"startTime":"0","endTime":"0","summary":"11月6日 - Amylyx Pharmaceuticals 第三季度经营收入为-3602.7万美元，而IBES预估为-4310万美元。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","AMLX"],"gpt_icon":0},{"id":"2581159270","title":"Amylyx Pharmaceuticals, Inc.盘中异动 早盘快速下挫6.42%","url":"https://stock-news.laohu8.com/highlight/detail?id=2581159270","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2581159270?lang=zh_cn&edition=full","pubTime":"2025-11-06 22:34","pubTimestamp":1762439643,"startTime":"0","endTime":"0","summary":"北京时间2025年11月06日22时34分，Amylyx Pharmaceuticals, Inc.股票出现波动，股价大幅跳水6.42%。Amylyx Pharmaceuticals, Inc.股票所在的生物技术行业中，整体跌幅为0.02%。其相关个股中，Iovance Biotherapeutics, Inc.、Cytomed Therapeutics Limited、Pharming Group Nv涨幅较大，Osr Holdings, Inc.、Polyrizon Ltd.、Lunai Bioworks Inc.较为活跃，换手率分别为84.48%、11.30%、6.70%，振幅较大的相关个股有Osr Holdings Inc C/Wts 09/02/2028 、Cartesian Therapeutics, Inc.、Sangamo Therapeutics, Inc.，振幅分别为20.60%、15.91%、11.78%。Amylyx Pharmaceuticals, Inc.公司简介：Amylyx Pharmaceuticals Inc 是一家处于临床阶段的制药公司，致力于开发治疗肌萎缩性侧索硬化症和其他神经退行性疾病的新型疗法。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251106223403a6e634f2&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251106223403a6e634f2&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["AMLX","BK4007"],"gpt_icon":0},{"id":"2577531604","title":"Amylyx Pharmaceuticals, Inc.盘中异动 大幅下跌5.04%报14.52美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2577531604","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2577531604?lang=zh_cn&edition=full","pubTime":"2025-10-22 23:22","pubTimestamp":1761146527,"startTime":"0","endTime":"0","summary":"北京时间2025年10月22日23时22分，Amylyx Pharmaceuticals, Inc.股票出现波动，股价快速下跌5.04%。Amylyx Pharmaceuticals, Inc.股票所在的生物技术行业中，整体跌幅为0.39%。Amylyx Pharmaceuticals, Inc.公司简介：Amylyx Pharmaceuticals Inc 是一家处于临床阶段的制药公司，致力于开发治疗肌萎缩性侧索硬化症和其他神经退行性疾病的新型疗法。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251022232207a46ed25e&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251022232207a46ed25e&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["AMLX","BK4007"],"gpt_icon":0},{"id":"2573178910","title":"Amylyx Pharmaceuticals, Inc.盘中异动 股价大涨5.00%报13.33美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2573178910","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2573178910?lang=zh_cn&edition=full","pubTime":"2025-10-08 03:51","pubTimestamp":1759866661,"startTime":"0","endTime":"0","summary":"北京时间2025年10月08日03时51分，Amylyx Pharmaceuticals, Inc.股票出现波动，股价大幅拉升5.00%。Amylyx Pharmaceuticals, Inc.股票所在的生物技术行业中，整体涨幅为0.53%。其相关个股中，Galecto, Inc.、Spruce Biosciences, Inc.、Nls Pharmaceutics Ltd C/Wts 02/02/2026涨幅较大，Galecto, Inc.、Indaptus Therapeutics, Inc.、Spruce Biosciences, Inc.较为活跃，换手率分别为5738.57%、534.57%、353.29%，振幅较大的相关个股有Galecto, Inc.、Nls Pharmaceutics Ltd C/Wts 02/02/2026、Processa Pharmaceuticals, Inc.，振幅分别为412.40%、91.72%、72.97%。Amylyx Pharmaceuticals, Inc.公司简介：Amylyx Pharmaceuticals Inc 是一家处于临床阶段的制药公司，致力于开发治疗肌萎缩性侧索硬化症和其他神经退行性疾病的新型疗法。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251008035101a6b001b0&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251008035101a6b001b0&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4007","AMLX"],"gpt_icon":0},{"id":"2566600138","title":"Amylyx股价上涨10.9%，此前完成1.75亿美元融资","url":"https://stock-news.laohu8.com/highlight/detail?id=2566600138","media":"环球市场播报","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2566600138?lang=zh_cn&edition=full","pubTime":"2025-09-10 22:51","pubTimestamp":1757515860,"startTime":"0","endTime":"0","summary":"美股周三早盘，制药商Amylyx Pharmaceuticals（AMLX）股价上涨10.9%，此前该公司宣布以每股10美元的价格完成1.75亿美元的公开发行，募集资金将用于商业化准备及研发。\n\n\n海量资讯、精准解读，尽在新浪财经APP\n\n责任编辑：张俊 SF065","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/usstock/c/2025-09-10/doc-infpzray3943805.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["AMLX","BK4007"],"gpt_icon":0},{"id":"1128800144","title":"Amylyx Pharmaceuticals宣布1.75亿美元普通股承销公开发行定价","url":"https://stock-news.laohu8.com/highlight/detail?id=1128800144","media":"美股速递","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1128800144?lang=zh_cn&edition=full","pubTime":"2025-09-10 12:07","pubTimestamp":1757477237,"startTime":"0","endTime":"0","summary":"Amylyx Pharmaceuticals宣布1.75亿美元普通股承销公开发行定价。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AMLX","BK4007"],"gpt_icon":0},{"id":"1163228347","title":"Amylyx Pharmaceuticals主动申请撤销ALS治疗药物Relyvrio的批准，FDA已批准该请求","url":"https://stock-news.laohu8.com/highlight/detail?id=1163228347","media":"美股速递","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1163228347?lang=zh_cn&edition=full","pubTime":"2025-08-28 23:47","pubTimestamp":1756396039,"startTime":"0","endTime":"0","summary":"Amylyx Pharmaceuticals公司已向FDA提交自愿申请，要求撤销其ALS治疗药物Relyvrio的批准，FDA已同意该撤销申请。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","AMLX"],"gpt_icon":0},{"id":"1168926790","title":"FDA撤回Amylyx Pharmaceuticals的Relyvrio悬浮剂新药申请批准","url":"https://stock-news.laohu8.com/highlight/detail?id=1168926790","media":"美股速递","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1168926790?lang=zh_cn&edition=full","pubTime":"2025-08-28 20:49","pubTimestamp":1756385356,"startTime":"0","endTime":"0","summary":"FDA宣布撤回Amylyx Pharmaceuticals持有的Relyvrio悬浮剂（3克/包、1克/包规格）的新药申请批准。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AMLX","BK4007"],"gpt_icon":0},{"id":"1118799174","title":"Amylyx Pharmaceuticals将终止针对进行性核上性麻痹的Amx0035药物Orion项目","url":"https://stock-news.laohu8.com/highlight/detail?id=1118799174","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1118799174?lang=zh_cn&edition=full","pubTime":"2025-08-27 19:02","pubTimestamp":1756292561,"startTime":"0","endTime":"0","summary":"Amylyx Pharmaceuticals宣布将终止其针对进行性核上性麻痹(PSP)的Amx0035药物Orion项目。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AMLX","BK4007"],"gpt_icon":0},{"id":"1180661356","title":"异动解读 | 高盛研报利好，Amylyx制药盘中大涨5.12%","url":"https://stock-news.laohu8.com/highlight/detail?id=1180661356","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1180661356?lang=zh_cn&edition=full","pubTime":"2025-08-13 03:02","pubTimestamp":1755025346,"startTime":"0","endTime":"0","summary":"生物科技公司Amylyx制药股价今日盘中大涨5.12%，引起投资者广泛关注。这一涨幅很可能与高盛最新发布的研究报告有关。高盛最新研报以\"2Q25 EPS更新\"为主题，重点分析了包括Amylyx在内的多家生物科技公司。这一积极评估似乎提振了投资者信心，推动Amylyx股价上涨。虽然报告提到部分公司可能因现金流或临床节点而略微调整目标价，但Amylyx并未被明确提及需要调整。投资者们将密切关注Amylyx未来的财报和临床试验结果，以验证这一乐观情绪是否合理。","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["AMLX"],"gpt_icon":0},{"id":"2558850641","title":"高盛最新研报以“2Q25 EPS更新”为主题其中重点对Amylyx(AMLX.US)、CG Oncology(CGON.","url":"https://stock-news.laohu8.com/highlight/detail?id=2558850641","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2558850641?lang=zh_cn&edition=full","pubTime":"2025-08-12 19:17","pubTimestamp":1754997464,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["IE0004086264.USD","IDYA","IE00B19Z3581.USD","BK4552","IE00BGHQF748.EUR","BK4599","BK4139","LU1894683348.USD","IE00BSNM7G36.USD","AMLX","159837","LU2237443978.SGD","LU2237438978.USD","159399","BK4533","GPCR","IE0004091025.USD","CGON","LU2750360997.AUD","BK4585","BK4550","LU1668664300.SGD","LU1868837300.USD","LU2237443622.USD","LU2471134879.HKD","LU0096364046.USD","LU1868837136.USD","IE00B64PRP62.GBP","LU0251131958.USD","IE00B3QW5Z07.USD","LU2471134796.USD","BK4127","LU0742534661.SGD","LU2750360641.GBP","LU1868836914.USD","BK4516","LU0061475181.USD","LU1868836757.USD","LU2237443549.SGD","LU2471134952.CNY","LU0048573561.USD","IE00B19Z3B42.SGD","LU2237443465.HKD","IE00BFXG1179.USD","CG","LU2237443895.HKD","LU1868836591.USD","BK4135","BK4504"],"gpt_icon":0},{"id":"2557562976","title":"Amylyx Pharmaceuticals, Inc.盘中异动 早盘股价大跌5.13%报7.77美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2557562976","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2557562976?lang=zh_cn&edition=full","pubTime":"2025-08-07 23:04","pubTimestamp":1754579071,"startTime":"0","endTime":"0","summary":"北京时间2025年08月07日23时04分，Amylyx Pharmaceuticals, Inc.股票出现异动，股价急速下挫5.13%。Amylyx Pharmaceuticals, Inc.股票所在的生物技术行业中，整体跌幅为0.27%。Amylyx Pharmaceuticals, Inc.公司简介：Amylyx Pharmaceuticals Inc 是一家处于临床阶段的制药公司，致力于开发治疗肌萎缩性侧索硬化症和其他神经退行性疾病的新型疗法。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250807230431a6d91cc1&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250807230431a6d91cc1&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4007","AMLX"],"gpt_icon":0},{"id":"2552207121","title":"Amylyx Pharmaceuticals, Inc.盘中异动 临近收盘股价大涨5.05%","url":"https://stock-news.laohu8.com/highlight/detail?id=2552207121","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2552207121?lang=zh_cn&edition=full","pubTime":"2025-07-17 03:40","pubTimestamp":1752694800,"startTime":"0","endTime":"0","summary":"北京时间2025年07月17日03时40分，Amylyx Pharmaceuticals, Inc.股票出现波动，股价大幅拉升5.05%。Amylyx Pharmaceuticals, Inc.股票所在的生物技术行业中，整体涨幅为1.35%。Amylyx Pharmaceuticals, Inc.公司简介：Amylyx Pharmaceuticals Inc 是一家处于临床阶段的制药公司，致力于开发治疗肌萎缩性侧索硬化症和其他神经退行性疾病的新型疗法。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250717034000a6ae0b0e&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250717034000a6ae0b0e&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4007","AMLX"],"gpt_icon":0},{"id":"2551193978","title":"Amylyx Pharmaceuticals, Inc.盘中异动 快速下跌5.09%报7.98美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2551193978","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2551193978?lang=zh_cn&edition=full","pubTime":"2025-07-15 22:28","pubTimestamp":1752589698,"startTime":"0","endTime":"0","summary":"北京时间2025年07月15日22时28分，Amylyx Pharmaceuticals, Inc.股票出现波动，股价大幅下挫5.09%。Amylyx Pharmaceuticals, Inc.股票所在的生物技术行业中，整体跌幅为0.14%。Amylyx Pharmaceuticals, Inc.公司简介：Amylyx Pharmaceuticals Inc 是一家处于临床阶段的制药公司，致力于开发治疗肌萎缩性侧索硬化症和其他神经退行性疾病的新型疗法。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025071522281897a7291b&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025071522281897a7291b&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["AMLX","BK4007"],"gpt_icon":0},{"id":"2551184049","title":"Amylyx Pharmaceuticals, Inc.盘中异动 股价大涨5.73%","url":"https://stock-news.laohu8.com/highlight/detail?id=2551184049","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2551184049?lang=zh_cn&edition=full","pubTime":"2025-07-14 21:30","pubTimestamp":1752499858,"startTime":"0","endTime":"0","summary":"北京时间2025年07月14日21时30分，Amylyx Pharmaceuticals, Inc.股票出现异动，股价快速拉升5.73%。Amylyx Pharmaceuticals, Inc.股票所在的生物技术行业中，整体涨幅为0.00%。其相关个股中，Dare Bioscience, Inc.、Sonnet Biotherapeutics Holdings, Inc.、Biomx Inc.涨幅较大，Windtree Therapeutics, Inc.、Sonnet Biotherapeutics Holdings, Inc.、Dare Bioscience, Inc.较为活跃，换手率分别为1599.55%、454.36%、301.17%，振幅较大的相关个股有Biomx Inc.、Kairos Pharma, Ltd.、Sonnet Biotherapeutics Holdings, Inc.，振幅分别为9.04%、6.89%、5.80%。Amylyx Pharmaceuticals, Inc.公司简介：Amylyx Pharmaceuticals Inc 是一家处于临床阶段的制药公司，致力于开发治疗肌萎缩性侧索硬化症和其他神经退行性疾病的新型疗法。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250714213058a6a8efa7&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250714213058a6a8efa7&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["AMLX","BK4007"],"gpt_icon":0},{"id":"1106700622","title":"Amylyx Pharma 第四季度每股收益$(0.55) 未达到预期$(0.52)","url":"https://stock-news.laohu8.com/highlight/detail?id=1106700622","media":"财报速递","labels":["express"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1106700622?lang=zh_cn&edition=full","pubTime":"2025-03-04 19:14","pubTimestamp":1741086875,"startTime":"0","endTime":"0","summary":"Amylyx Pharma报告季度每股亏损$，低于分析师共识预期的$，低了5.77%。相比去年同期每股收益$0.07，这一结果下降了885.71%。以上内容来自Benzinga Earnings专栏，原文如下：Amylyx Pharma  reported quarterly losses of $ per share which missed the analyst consensus estimate of $ by 5.77 percent. This is a 885.71 percent decrease over earnings of $0.07 per share from the same period last year.  The company reported $ in sales this quarter. This is a 100.61 percent decrease over sales of $108.45 million the same period last year.","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Amylyx Pharma 第四季度每股收益$(0.55) 未达到预期$(0.52)","news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AMLX"],"gpt_icon":0},{"id":"2488944791","title":"Amylyx Pharmaceuticals, Inc.盘中异动 早盘股价大跌5.02%","url":"https://stock-news.laohu8.com/highlight/detail?id=2488944791","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2488944791?lang=zh_cn&edition=full","pubTime":"2024-12-03 23:16","pubTimestamp":1733238980,"startTime":"0","endTime":"0","summary":"北京时间2024年12月03日23时16分，Amylyx Pharmaceuticals, Inc.股票出现异动，股价急速下跌5.02%。Amylyx Pharmaceuticals, Inc.股票所在的生物技术行业中，整体跌幅为0.48%。Amylyx Pharmaceuticals, Inc.公司简介：Amylyx Pharmaceuticals Inc是一家临床阶段的制药公司，致力于开发一种治疗肌萎缩性侧索硬化症和其他神经退行性疾病的新疗法。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241203231620a269acce&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241203231620a269acce&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4007","AMLX"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.amylyx.com","stockEarnings":[{"period":"1week","weight":0.0692},{"period":"1month","weight":-0.0771},{"period":"3month","weight":-0.1438},{"period":"6month","weight":0.5898},{"period":"1year","weight":2.2387},{"period":"ytd","weight":0.0108}],"compareEarnings":[{"period":"1week","weight":0.016},{"period":"1month","weight":0.0095},{"period":"3month","weight":0.0629},{"period":"6month","weight":0.113},{"period":"1year","weight":0.1774},{"period":"ytd","weight":0.0178}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Amylyx Pharmaceuticals, Inc.于2014年1月10日根据特拉华州法律成立。该公司是一家临床阶段的制药公司，其使命是为医疗需求未得到满足的社区开发和推进新疗法。该公司在神经退行性疾病和内分泌疾病方面正在进行临床前和临床开发项目。该公司正在推进一项管道，在该管道中，该公司已将研究性疗法与认为这些疗法可以产生最大影响的疾病相匹配，基于明确定义的机制原理、明确的临床结果和生物标志物，以及严格的临床前数据，与模式无关。","yearOnYearQuotes":[{"month":1,"riseRate":0.75,"avgChangeRate":0.030987},{"month":2,"riseRate":0.5,"avgChangeRate":0.096144},{"month":3,"riseRate":0.25,"avgChangeRate":-0.384218},{"month":4,"riseRate":0.25,"avgChangeRate":-0.062706},{"month":5,"riseRate":0.25,"avgChangeRate":-0.046188},{"month":6,"riseRate":0.75,"avgChangeRate":0.347356},{"month":7,"riseRate":1,"avgChangeRate":0.206362},{"month":8,"riseRate":0.5,"avgChangeRate":0.025088},{"month":9,"riseRate":0.75,"avgChangeRate":0.218209},{"month":10,"riseRate":0.75,"avgChangeRate":0.212399},{"month":11,"riseRate":0.75,"avgChangeRate":0.011294},{"month":12,"riseRate":0.25,"avgChangeRate":-0.127185}],"exchange":"NASDAQ","name":"Amylyx Pharmaceuticals","nameEN":"Amylyx Pharmaceuticals"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.36.0","shortVersion":"4.36.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Amylyx Pharmaceuticals(AMLX)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供Amylyx Pharmaceuticals(AMLX)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"Amylyx Pharmaceuticals,AMLX,Amylyx Pharmaceuticals股票,Amylyx Pharmaceuticals股票老虎,Amylyx Pharmaceuticals股票老虎国际,Amylyx Pharmaceuticals行情,Amylyx Pharmaceuticals股票行情,Amylyx Pharmaceuticals股价,Amylyx Pharmaceuticals股市,Amylyx Pharmaceuticals股票价格,Amylyx Pharmaceuticals股票交易,Amylyx Pharmaceuticals股票购买,Amylyx Pharmaceuticals股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Amylyx Pharmaceuticals(AMLX)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供Amylyx Pharmaceuticals(AMLX)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}